ArticleInternational journal of molecular sciences2025
Subtype-Specific mRNA Signatures of Human Ribosomal Proteins in Pediatric Cancers.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
A growing body of recent work suggests the possibility of heterogeneous ribosomal composition. We recently observed subtype-specific mRNA and copy number variation signatures of human ribosomal proteins (RPs) in cancers from human adults, but whether such subtype-specific RP mRNA signatures are also present in human pediatric cancers is currently unknown. In this study, we analyzed mRNA expression data from multiple large pediatric cancer datasets to test for heterogeneity in RP mRNA signatures. We found that different pediatric cancer types have different RP mRNA signatures, sometimes multiple RP mRNA signatures within the same pediatric cancer type, which can be subgroup/subtype-specific (e.g., in Medulloblastoma) or cell-of-origin-specific (e.g., in Acute Lymphoblastic Leukemia (ALL)). In B-cell ALL, we found two RP mRNA subtypes with significantly different prognoses. Consistent with our recent findings in adult cancers, the RP mRNA signature in pediatric cancer is heterogeneous and subtype-specific and may have clinical relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.